Tidal Investments LLC Has $1.35 Million Stock Position in Royalty Pharma plc (NASDAQ:RPRX)

Tidal Investments LLC reduced its position in shares of Royalty Pharma plc (NASDAQ:RPRX) by 1.3% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 47,746 shares of the biopharmaceutical company’s stock after selling 625 shares during the quarter. Tidal Investments LLC’s holdings in Royalty Pharma were worth $1,351,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently added to or reduced their stakes in the business. Swedbank AB raised its stake in shares of Royalty Pharma by 2.0% during the third quarter. Swedbank AB now owns 11,027,370 shares of the biopharmaceutical company’s stock worth $311,964,000 after buying an additional 213,900 shares during the last quarter. State Street Corp raised its position in shares of Royalty Pharma by 0.3% during the 3rd quarter. State Street Corp now owns 9,516,262 shares of the biopharmaceutical company’s stock valued at $269,215,000 after acquiring an additional 29,451 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Royalty Pharma by 6.1% in the 3rd quarter. Geode Capital Management LLC now owns 7,265,786 shares of the biopharmaceutical company’s stock valued at $205,562,000 after purchasing an additional 417,490 shares during the period. Two Sigma Advisers LP boosted its position in shares of Royalty Pharma by 44.7% in the 3rd quarter. Two Sigma Advisers LP now owns 3,033,200 shares of the biopharmaceutical company’s stock worth $85,809,000 after purchasing an additional 936,900 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its stake in shares of Royalty Pharma by 58.1% during the third quarter. Charles Schwab Investment Management Inc. now owns 3,001,603 shares of the biopharmaceutical company’s stock worth $84,915,000 after purchasing an additional 1,103,341 shares during the period. 54.35% of the stock is currently owned by institutional investors and hedge funds.

Royalty Pharma Trading Down 2.6 %

NASDAQ:RPRX opened at $24.47 on Thursday. The business’s 50-day simple moving average is $26.55 and its 200-day simple moving average is $27.19. Royalty Pharma plc has a fifty-two week low of $24.46 and a fifty-two week high of $31.66. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.54 and a quick ratio of 1.54. The stock has a market capitalization of $14.42 billion, a PE ratio of 12.68, a price-to-earnings-growth ratio of 4.36 and a beta of 0.46.

Royalty Pharma Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, December 10th. Stockholders of record on Friday, November 15th were issued a $0.21 dividend. This represents a $0.84 annualized dividend and a dividend yield of 3.43%. The ex-dividend date was Friday, November 15th. Royalty Pharma’s dividend payout ratio (DPR) is presently 43.52%.

Analysts Set New Price Targets

A number of brokerages have issued reports on RPRX. StockNews.com upgraded Royalty Pharma from a “hold” rating to a “buy” rating in a report on Tuesday, November 5th. Citigroup reduced their price objective on shares of Royalty Pharma from $60.00 to $40.00 and set a “buy” rating on the stock in a research note on Friday, October 25th. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $41.67.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.